Article
Author(s):
Roche has launched a new HbA1C test to identify diabetes risk and diagnose and monitor patients with diabetes.
Roche has launched a new HbA1C test to identify diabetes risk and diagnose and monitor patients with diabetes.
The cobas c 513 analyzer will replace Roche’s existing HbA1C product, the cobas integra 800 CTS, and will double the throughput of the previous product from 200 to 400 patient results per hour.
The new analyzer provides direct results reporting, which can reduce the risk of data misinterpretation and save time for researchers. It also has higher on-board test capacity, according to Roche.
This allows laboratories to load the analyzer with more tests, saving space and increasing overall efficiency. The device also includes closed-tube sampling, which reduces hands-on time and contamination risk.
“The increasing number of people with diabetes is challenging health care providers and is putting a significant strain on health care systems,” said Roland Diggelmann, chief operating officer of Roche Diagnostics. “With the cobas c 513, Roche is meeting the dedicated and growing testing needs of our customers.”